[{"orgOrder":0,"company":"Terray Therapeutics","sponsor":"Bedford Ridge Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Terray Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Terray Therapeutics \/ Bedford Ridge Capital","highestDevelopmentStatusID":"12","companyTruncated":"Terray Therapeutics \/ Bedford Ridge Capital"},{"orgOrder":0,"company":"Terray Therapeutics","sponsor":"Odyssey Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Terray Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Terray Therapeutics \/ Terray Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Terray Therapeutics \/ Terray Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Terray Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across immune and inflammatory diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Recipient : Odyssey Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova, which it uses to power both internal and partnered programs.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Bedford Ridge Capital

                          Deal Size : $120.0 million

                          Deal Type : Series B Financing

                          blank